Compare CTLP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTLP | VALN |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 798.9M | 875.7M |
| IPO Year | N/A | N/A |
| Metric | CTLP | VALN |
|---|---|---|
| Price | $9.98 | $10.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 1.6M | 12.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.11 | $3.64 |
| Revenue Next Year | $14.37 | $12.23 |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.01 | $5.43 |
| 52 Week High | $11.36 | $12.25 |
| Indicator | CTLP | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 19.74 | 67.90 |
| Support Level | $10.37 | $9.95 |
| Resistance Level | $10.74 | $10.40 |
| Average True Range (ATR) | 0.17 | 0.29 |
| MACD | -0.07 | 0.10 |
| Stochastic Oscillator | 1.11 | 98.04 |
Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.